Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

de Bono, Johann; Oudard, Stephane; Ozguroglu, Mustafa; Hansen, Steinbjorn; Machiels, Jean-Pascal; Kocak, Ivo; Gravis, Gwenaelle; Bodrogi, Istvan; Mackenzie, Mary; Shen, Liji; Roessner, Martin; Gupta, Sunil; Sartor, A.

doi:10.1016/s0140-6736(10)61389-x

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

Atıf İçin Kopyala

de Bono J. S., Oudard S., Ozguroglu M., Hansen S., Machiels J., Kocak I., ...Daha Fazla

LANCET, cilt.376, sa.9747, ss.1147-1154, 2010 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 376 Sayı: 9747
Basım Tarihi: 2010
Doi Numarası: 10.1016/s0140-6736(10)61389-x
Dergi Adı: LANCET
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1147-1154
İstanbul Üniversitesi Adresli: Evet

Özet

Background Cabazitaxel is a novel tubulin-binding taxane drug with antitumour activity in docetaxel-resistant cancers. We aimed to compare the efficacy and safety of cabazitaxel plus prednisone with those of mitoxantrone plus prednisone in men with metastatic castration-resistant prostate cancer with progressive disease after docetaxel-based treatment.